CHAPTER 2 Weight Loss Products
Obesity is an urgent and growing health problem in the United States. The U.S. Surgeon General reports that the risks of overweight and obesity may soon cause as much morbidity and mortality as does cigarette smoking. The prevalence of obesity in the United States is increasing to epidemic proportions. At present, more than 60% of Americans are overweight.1
Overweight and obesity are determined by measurement of body mass index (BMI), which is a measure of weight for height generally defined as weight in kilograms divided by the square of height in meters. A BMI of 25 to 29.9 in an adult indicates that the individual is overweight; obesity is defined as a BMI of 30 or greater (Table 2-1). The Centers for Disease Control and Prevention (CDC) has developed special charts to calculate BMI in children and adolescents. Overweight and obesity have been associated with a constellation of major risk factors and life habit risk factors that constitute a condition called the metabolic syndrome. The CDC estimates that one in five adults in the United States already has metabolic syndrome and this number is growing. Evidence indicates that metabolic syndrome is a major risk factor for cardiovascular disease and diabetes. The root causes of metabolic syndrome are poor diet, obesity, and sedentary lifestyle (Box 2-1).
| BODY MASS INDEX | WEIGHT STATUS |
|---|---|
| Below 18.5 | Underweight |
| 18.5-24.9 | Normal |
| 25.0-29.9 | Overweight |
| ≥30.0 | Obese |
From http://www.cdc.gov/nccdphp/dnpa/bmi/calc-bmi.htm#English.
Box 2-1 Diagnostic criteria for metabolic syndrome
Metabolic syndrome is a cluster of at least three of the following signs:
DIETARY SUPPLEMENTS AND WEIGHT LOSS
Most dietary supplements currently used for weight loss are adrenergic stimulants or antiabsorptive agents. The adrenergic stimulants, such as ephedra, have been associated with adverse central nervous system and cardiovascular effects. The antiabsorptive agents appear to be safer than the adrenergic stimulants but can cause gastrointestinal side effects.
Ephedra (Ephedra sinica, E. equisentina, E. intermedia)
Ephedra, also known as ma-huang, was widely sold as a dietary supplement for weight loss and to enhance athletic performance in the United States until February 2004. Before its introduction in the West, Asian populations had used ephedra as an herbal remedy for asthma, cough, headache, fever, allergies, and congestion for more than 5000 years. Ephedra is the common name for three principal species: Ephedra sinica, E. equisentina, and E. intermedia. Asian species of ephedra contain varying amounts of pharmacologically active ephedrine alkaloids, mainly ephedrine and pseudoephedrine, whereas North American species (commonly referred to as Mormon tea) contain small amounts or are devoid of these alkaloids.1 Ephedrine was first isolated from ephedra in 1887 by Japanese chemist N. Nagai but did not gain popularity in the West until K.K. Chen and Carl F. Schmidt published a series of studies on the pharmacological properties of ephedrine in the 1920s.2 Research has shown that ephedrine stimulates heart rate, resulting in increased cardiac output, while constricting peripheral blood vessels, which leads to increased peripheral resistance and blood pressure.3 Ephedrine relaxes bronchial smooth muscle, which explains its long history of use in the treatment of asthma.3
Efficacy.
Ephedra has become one of the most controversial herbs on the U.S. market. Because so many questions have been raised with regard to the safety and efficacy of ephedra-containing products for weight loss and “energy enhancement,” the government commissioned a review of the data to determine what action, if any, should be taken with regard to the sale of these products. The Rand Group conducted a meta-analysis of 20 trials of ephedra or ephedrine for weight loss. Of the 20 studies, only five tested herbal ephedra formulations as contained in products. Most of the studies were limited by methodological problems (particularly high attrition rates, which are typical with the use of weight loss products), and the reviewers noted that this might have contributed to bias. Nevertheless, their findings support an association between the short-term use of ephedrine, ephedrine plus caffeine, or dietary supplements that contain ephedra (with or without herbs containing caffeine) and a statistically significant increase in short-term weight loss compared with that seen with placebo. Both ephedra and ephedrine result in weight loss of approximately 2 lb per month more than that with placebo for as long as 4 to 6 months.4
The findings of the Rand Group review are reflected in another recent study, a randomized, double-blind, placebo-controlled trial of 167 subjects given a product containing 90 mg of ephedrine and 192 mg of caffeine per day as an adjunct to diet and exercise for 6 months.5 The treated group lost 4.0 kg, compared with 0.8 kg in the placebo group. In addition to the weight loss noted in the treatment group, 23% of the treatment group withdrew after experiencing adverse effects, which included hypertension, chest pain, and palpitations. No participants withdrew from the placebo group. Translation of these fndings to to the general population of overweight Americans, many of whom may have undiagnosed hypertension or heart disease, should raise concerns.
Safety.
The government-commissioned review of ephedra products also included a safety analysis based on controlled trials. The use of ephedrine, ephedra-containing dietary supplements, or ephedrine plus caffeine is associated with two or three times the risk of nausea, vomiting, psychiatric symptoms such as anxiety or change in mood, autonomic hyperactivity, and palpitations compared with placebo. However, the numbers of people treated in the clinical trials were quite small, thereby limiting a true estimate of risk. Therefore the Rand Group also reviewed 71 cases reported in the published medical literature, 1820 case reports provided by the U.S. Food and Drug Administration (FDA), and more than 18,000 consumer complaints reported to a manufacturer of ephedra-containing dietary supplements.4
Because most of the cases lacked appropriate documentation, only 65 cases from the published literature, 241 cases from the FDA, and 43 cases from the manufacturer were included in the analysis of adverse events. Reviewers found that sentinel events with prior ephedra consumption included two deaths, three myocardial infarctions, nine cerebrovascular/stroke events, three seizures, and five psychiatric cases. Sentinel events with prior ephedrine consumption included three deaths, two myocardial infarctions, two cerebrovascular/stroke events, one seizure, and three psychiatric cases. Approximately half of the sentinel events occurred in people 30 years of age or younger. An additional 43 cases were identified as possible sentinel events with prior ephedra consumption, and an additional seven cases were identified as possible sentinel events with prior ephedrine consumption.
Marketing.
The marketing and promotion of ephedra/caffeine-containing products for weight loss and energy enhancement on the Internet has been a concern from a public safety perspective. Thirty-two products and advertisements were identified and systematically evaluated for deviance from truth-in-advertising standards. Of the 32 Web sites analyzed, 13 (41%) failed to disclose potential adverse effects or contraindications to supplement use. Seventeen (53%) did not reveal the recommended dosage of ephedra alkaloids. More important, 11 sites (34%) contained incorrect or misleading statements, some of which could directly result in serious harm to consumers.6 Certain individuals, including those with heart disease, cerebrovascular disease, hypertension, diabetes, thyroid disease, and enlarged prostate, should not use these products. These supplements should not be taken by women who are pregnant or breastfeeding or by individuals taking certain psychiatric medications.
Summary.
Ephedra is used in small doses in traditional Chinese medicine as, well as in Western herbal medicine, primarily for respiratory problems; this use does not appear to be dangerous. Virtually all adverse effects reported with ephedra have been associated with products intended for weight loss, exercise enhancement, energy enhancement, or recreational use, none of which is a traditional indication and all of which involve doses designed to increase metabolism.7 Although some evidence indicates that these products can cause weight loss in the short term, the long-term safety and efficacy of ephedra with and without caffeine are unknown.
Dietary supplements containing ephedrine alkaloids present an unreasonable risk of illness or injury under conditions of use recommended or suggested in the labeling, or if no conditions of use are recommended or suggested in the labeling, under ordinary conditions of use. Therefore, dietary supplements containing ephedrine alkaloids are adulterated under section 402(f)(1)(A) of the Federal Food, Drug, and Cosmetic Act.8
Bitter Orange (Citrus aurantium)
Citrus aurantium (also known as bitter, sour, or Seville orange) originated in China and seems to have entered the written record there by 300 BC. By about 100 BC, C. aurantium seeds appear to have reached Rome. The dried orange peel was traditionally used as a digestive tonic and flavoring agent. The German Commission E recognizes the use of dried C. aurantium peel for dyspeptic complaints and loss of appetite.9 Many companies are substituting C. aurantium for ephedra in their weight loss formulations as a result of the unfavorable publicity of ephedra in the media. The use of C. aurantium will likely grow now that the ephedra ban is in place. C. aurantium is made from the dried outer part of the pericarp of the ripe or nearly ripe fruit.10 It contains synephrine and octopamine, among other compounds, and has been reported in two studies to aid weight loss and in three to increase thermogenesis, at least to some extent.11 Synephrine and octopamine are phenolamines found in sympathetic nerve fibers. Synephrine is similar to adrenaline, and octopamine is similar to noradrenaline (differing only in the number of hydroxyl groups on the aromatic ring).12 Synephrine activates both α-adrenoreceptors and β3-adrenoreceptors; both synephrine and octopamine inhibit production of cyclic adenosine monophosphate. β3-Adrenoreceptor agonists are full lipolytic agents in rats, hamsters, and dogs but are less active in human beings.7
A double-blind, randomized, placebo-controlled, three-armed study of 23 subjects with BMIs of more than 25 kg/m2 compared treatment, placebo, and no intervention as an adjunct to a 1800-calorie American Heart Association step I diet and a weight circuit training exercise program 3 days a week under the direction of an exercise physiologist.13 The treatment product tested contained a daily dosage of 975 mg of C. aurantium extract (6% synephrine alkaloids), 528 mg of caffeine, and 900 mg of St. John’s wort (3% hypericum) and was administered for 6 weeks. Outcome measures included weight, fat loss, and mood. Twenty subjects completed the study. Treated subjects lost a significant amount of weight (mean 1.4 kg) compared with the placebo group (mean 0.9 kg) and control group (mean 0.04 kg). However, the table in the article appears to indicate that the differences are significant compared with the baseline but not between groups. The amount of caffeine in this product is the rough equivalent of four cups of coffee or 10 cups of tea. The treatment group lost 2.9% body fat; no significant change was noted in the placebo and control groups. The researchers detected no significant changes in any group in a questionnaire profiling the subjects’ mood states or in blood lipid levels, blood pressure, heart rate, electrocardiographic findings, serum chemistry values, or urinalysis. The treated group demonstrated a significant increase in basal metabolic rate, whereas the placebo group showed a significant decrease in basal metabolic rate; no change was noted in the no-treatment group. No side effects were reported. (NOTE: Although the trial lists the St. John’s wort as containing 3% hypericum, it likely means the product was standardized to 0.3% hypericin. Assuming that the 3% hypericum reported in the study actually means 0.3% hypericin, the dose of St. John’s wort in this product would be a therapeutic antidepressant dose.)
Small amounts of synephrine occur naturally in many citrus products. Human populations consume Seville, or sour-orange, juice without adverse effects. A crossover open-label safety study in 12 normotensive subjects ranging from 20 to 27 years of age was conducted to evaluate the cardiovascular effects of two doses of C. aurantium juice (8 oz, 8 hours apart). The test was repeated with water a week later. Blood pressure was measured every hour for 5 hours after the second dose of juice; systolic and diastolic blood pressure, mean arterial pressure, and heart rate were not significantly altered. It was estimated that the subjects consumed 13 or 14 mg of synephrine, comparable to a dose of phenylephrine in a decongestant-containing cold preparation.14
Pharmacokinetic data and safety studies have not been published on the high potency of synephrine-containing products. Any sympathomimetic agent in sufficient amounts can increase thermogenesis and cannot be presumed to be safe, especially in individuals with cardiovascular disease. C. aurantium extract has caused cardiac disturbances in animals.14 Extracts available on the Internet contain between 4% and 50% synephrine, far greater than the amount that occurs naturally in the fruit and rind (0.25% to 2%). The extracts sold in weight loss products do not represent the traditional uses or doses of the crude herb. C. aurantium, known as zhishi or chih-shih in traditional Chinese medicine, has been used safely in the treatment of epigastric pain, constipation, and other digestive disorders for centuries. The safety accorded to crude preparations of bitter-orange peel cannot be extrapolated to weight loss products containing highly concentrated levels of adrenergic compounds.
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree